# EDGAR Filing Document

**Accession Number:** 0001815442
**File Stem:** 0001193125-23-045632
**Filing Date:** 2023-2
**Character Count:** 19125
**Document Hash:** ad1935aa6276fdbabbe36cfe3b79cf4a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-23-045632.hdr.sgml**: 20230223

**ACCESSION NUMBER**: 0001193125-23-045632

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 5

**FILED AS OF DATE**: 20230223

**DATE AS OF CHANGE**: 20230223

**EFFECTIVENESS DATE**: 20230223

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Kymera Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001815442
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 812992166
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-269928
- **FILM NUMBER:** 23655939

**BUSINESS ADDRESS:**
- **STREET 1:** 200 ARSENAL YARDS BLVD., SUITE 230
- **CITY:** WATERTOWN
- **STATE:** MA
- **ZIP:** 02472
- **BUSINESS PHONE:** 857-285-5314

**MAIL ADDRESS:**
- **STREET 1:** 200 ARSENAL YARDS BLVD., SUITE 230
- **CITY:** WATERTOWN
- **STATE:** MA
- **ZIP:** 02472

**As filed with the Securities and Exchange Commission on February 23, 2023** 

**Registration No. 333-** 

------

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**WASHINGTON, D.C. 20549** 

------

**FORM S-8**

**REGISTRATION STATEMENT** 

***UNDER***

***THE SECURITIES ACT OF 1933***

------

## KYMERA THERAPEUTICS, INC.
**(Exact name of registrant as specified in its charter)** 

------

---

| | |
|:---|:---|
| **Delaware** | **81-2992166** |
| **(State or other jurisdiction of**<br> **incorporation or organization)** | **(I.R.S. Employer**<br> **Identification No.)** |

---

---

| | |
|:---|:---|
| **200 Arsenal Yards Blvd., Suite 230**<br> **Watertown, MA** | **02472** |
| **(Address of Principal Executive Offices)** | **(Zip Code)** |

---

**Kymera Therapeutics, Inc. 2020 Stock Option and Incentive Plan** 

**Kymera Therapeutics, Inc. Amended and Restated 2020 Employee Stock Purchase Plan** 

**(Full title of the plan)** 

**Nello Mainolfi, Ph.D.** 

**Founder, President and Chief Executive Officer** 

**Kymera Therapeutics, Inc.** 

**200 Arsenal Yards Blvd., Suite 230** 

**Watertown, MA 02472** 

**(Name and address of agent for service)** 

**617-300-8460** 

**(Telephone number, including area code, of agent for service)** 

------

***Copies to:***

**William D. Collins, Esq.** 

**Catherine Magazu, Esq.** 

**Goodwin Procter LLP** 

**100 Northern Avenue** 

**Boston, Massachusetts 02210** 

**(617) 570-1000**

------

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☒ | Accelerated filer | ☐ |
| Non-accelerated filer | ☐ | Smaller reporting company | ☐ |
|  |  | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

------

**EXPLANATORY NOTE** 

This Registration Statement on Form S-8 registers 2,201,575 additional shares of Common Stock under the Kymera Therapeutics, Inc. 2020 Stock Option and Incentive Plan (the "Plan") and 438,898 additional shares of Common Stock under the Kymera Therapeutics, Inc. Amended and Restated 2020 Employee Stock Purchase Plan (the "ESPP"). The number of shares of Common Stock reserved and available for issuance under the Plan is subject to an automatic annual increase on each January 1, beginning in 2021, by an amount equal to the lesser of: (i) four percent of the number of shares of Common Stock issued and outstanding on the immediately preceding December 31 or (ii) such number of shares of Common Stock as determined by the compensation committee of the Company's board of directors. Accordingly, on January 1, 2023, the number of shares of Common Stock reserved and available for issuance under the Plan increased by 2,201,575. The number of shares of Common Stock reserved and available for issuance under the ESPP is subject to an automatic annual increase on each January 1, beginning in 2021, by an amount equal to the least of: (i) one percent of the number of shares of Common Stock issued and outstanding on the immediately preceding December 31, (ii) 438,898 shares of Common Stock or (iii) such number of shares of Common Stock as determined by the Administrator (as defined in the ESPP). Accordingly, on January 1, 2023, the number of shares of Common Stock reserved and available for issuance under the ESPP increased by 438,898. The additional shares are of the same class as other securities relating to the Plan and the ESPP for which the Registrant's registration statements filed on Form S-8 filed with the Securities and Exchange Commission on August 21, 2020 (File No. 333-248249), March 11, 2021 (File No. 333-254122) and February 24, 2022 (File No. 333-262947), are effective. The information contained in the Registrant's registration statements on Form S-8 (Registration Nos. 333-248249, 333-254122 and 333-262947) are hereby incorporated by reference pursuant to General Instruction E.

------

**Part II** 

**<u>INFORMATION REQUIRED IN THE REGISTRATION STATEMENT</u>**

**Item 8. Exhibits.** 

---

| | |
|:---|:---|
| **Exhibit<br>No.** | **Description** |
| &nbsp;&nbsp;&nbsp;&nbsp;4.1 | [Fourth Amended and Restated Certificate of Incorporation of the Registrant (Incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K (File No. 001-39460) filed with the Securities and Exchange Commission on August 25, 2020.](http://www.sec.gov/Archives/edgar/data/1815442/000119312520229873/d45025dex31.htm) |
| &nbsp;&nbsp;&nbsp;&nbsp;4.2 | [Second Amended and Restated Bylaws of the Registrant (Incorporated by reference to Exhibit 3.2 to the Registrant's Current Report on Form 8-K (File No. 001-39460) filed with the Securities and Exchange Commission on August 25, 2020.](http://www.sec.gov/Archives/edgar/data/1815442/000119312520229873/d45025dex32.htm) |
| &nbsp;&nbsp;&nbsp;&nbsp;4.3 | [Specimen Common Stock Certificate of the Registrant (Incorporated by reference to Exhibit 4.1 to the Registrant's Registration Statement on Form S-1/A (File No. 333-240264) filed with the Securities and Exchange Commission on August 17, 2020).](http://www.sec.gov/Archives/edgar/data/1815442/000119312520221618/d940105dex41.htm) |
| &nbsp;&nbsp;&nbsp;&nbsp;4.4 | [Second Amended and Restated Investors' Rights Agreement by and among the Registrant and certain of its stockholders dated March 11, 2020 (Incorporated by reference to Exhibit 4.2 to the Registrant's Registration Statement on Form S-1 (File No. 333-240264) filed with the Securities and Exchange Commission on July 31, 2020).](http://www.sec.gov/Archives/edgar/data/1815442/000119312520206645/d940105dex42.htm) |
| &nbsp;&nbsp;&nbsp;&nbsp;5.1\* | [Opinion of Goodwin Procter LLP.](d446122dex51.htm) |
| 23.1\* | [Consent of Ernst & Young LLP, independent registered public accounting firm.](d446122dex231.htm) |
| 23.2\* | [Consent of Goodwin Procter LLP (included in Exhibit 5.1).](d446122dex51.htm) |
| 24.1\* | [Power of Attorney (included on signature page).](d446122ds8.htm#sig) |
| 99.1 | [2020 Stock Option and Incentive Plan and forms of award agreements thereunder (Incorporated by reference to Exhibit 10.2 to the Registrant's Registration Statement on Form S-1/A (File No. 333-240264) filed with the Securities and Exchange Commission on August 17, 2020).](http://www.sec.gov/Archives/edgar/data/1815442/000119312520221618/d940105dex102.htm) |
| 99.2 | [Amended and Restated 2020 Employee Stock Purchase Plan (Incorporated by reference to Exhibit 10.1 to the Registrant's Quarterly Report on Form 10-Q (File No. 001-39460) filed with the Securities and Exchange Commission on November 5, 2020).](http://www.sec.gov/Archives/edgar/data/1815442/000156459020050872/kymr-ex101_540.htm) |
| 107\* | [Filing Fee Table.](d446122dexfilingfees.htm) |

---

\* Filed herewith.

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Watertown, Commonwealth of Massachusetts, on February 23, 2023.

---

| | |
|:---|:---|
| **KYMERA THERAPEUTICS, INC.** | **KYMERA THERAPEUTICS, INC.** |
| By: | /s/ Nello Mainolfi |
|  | Name: Nello Mainolfi, Ph.D. |
|  | Title: Founder, President and Chief Executive Officer |

---

------

**POWER OF ATTORNEY AND SIGNATURES** 

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints each of Nello Mainolfi, Ph.D. and Bruce Jacobs, CFA, MBA as such person's true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution in each of them, for such person in such person's name, place and stead, in any and all capacities, to sign for us and in our names in the capacities indicated below the Registration Statement on Form S-8 of Kymera Therapeutics, Inc., and any or all amendments (including post-effective amendments), and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in connection therewith and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or substitutes of any of them, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement on Form S-8 has been signed by the following persons in the capacities and on the dates indicated.

------

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ Nello Mainolfi<br> Nello Mainolfi, Ph.D. | Director, Founder, President and Chief Executive Officer<br> (Principal Executive Officer) | February 23, 2023 |
| /s/ Bruce Jacobs<br> Bruce Jacobs, CFA, MBA | Chief Financial Officer<br>(Principal Financial Officer)<br>(Principal Accounting Officer) | February 23, 2023 |
| /s/ Jeffrey Albers<br> Jeffrey Albers, J.D., MBA | Director | February 23, 2023 |
| /s/ Bruce Booth<br> Bruce Booth, D.Phil. | Director | February 23, 2023 |
| /s/ Pamela Esposito<br> Pamela Esposito, Ph.D. | Director | February 23, 2023 |
| /s/ Joanna Horobin<br> Joanna Horobin, M.B., Ch.B. | Director | February 23, 2023 |
| /s/ Gorjan Hrustanovic<br> Gorjan Hrustanovic, Ph.D. | Director | February 23, 2023 |
| /s/ John Maraganore<br> John Maraganore, Ph.D. | Director | February 23, 2023 |
| /s/ Leigh Morgan<br> Leigh Morgan | Director | February 23, 2023 |
| /s/ Elena Ridloff<br> Elena Ridloff, CFA | Director | February 23, 2023 |
| /s/ Victor Sandor<br> Victor Sandor, M.D. | Director | February 23, 2023 |

---

## Exhibit 5.1

---

| | |
|:---|:---|
| ![LOGO](g446122g0222091318103.jpg) | Goodwin Procter LLP<br> 100 Northern Avenue<br> Boston, MA 02210  |
|  | goodwinlaw.com <br> +1 617 570 1000  |

---

**Exhibit 5.1** 

February 23, 2023

Kymera Therapeutics, Inc.

200 Arsenal Yards Blvd., Suite 230

Watertown, MA 02472

Re: <u>Securities Being Registered under Registration Statement on Form S-8</u>

We have acted as counsel to you in connection with your filing of a Registration Statement on Form S-8 (the "Registration Statement") pursuant to the Securities Act of 1933, as amended (the "Securities Act"), on or about the date hereof relating to an aggregate of (i) 2,201,575 shares (the "Plan Shares") of common stock, $0.0001 par value per share (the "Common Stock"), of Kymera Therapeutics, Inc., a Delaware corporation (the "Company"), that may be issued pursuant to the Kymera Therapeutics, Inc. 2020 Stock Option and Incentive Plan (the "Incentive Plan") and (ii) 438,898 shares (the "ESPP Shares" and together with the Plan Shares, the "Shares") of Common Stock of the Company that may be issued pursuant to the Amended and Restated Kymera Therapeutics, Inc. 2020 Employee Stock Purchase Plan (the "ESPP" and, together with the Incentive Plan, the "Plans").

We have reviewed such documents and made such examination of law as we have deemed appropriate to give the opinion set forth below. We have relied, without independent verification, on certificates of public officials and, as to matters of fact material to the opinion set forth below, on certificates of officers of the Company.

The opinion set forth below is limited to the Delaware General Corporation Law.

For purposes of the opinion set forth below, we have assumed that no event occurs that causes the number of authorized shares of Common Stock available for issuance by the Company to be less than the number of then unissued Shares.

Based on the foregoing, we are of the opinion that the Shares have been duly authorized and, upon issuance and delivery against payment therefor in accordance with the terms of the Plans, will be validly issued, fully paid and nonassessable.

This opinion letter and the opinion it contains shall be interpreted in accordance with the Core Opinion Principles as published in 74 *Business Lawyer* 815 (Summer 2019).

------

We hereby consent to the inclusion of this opinion as Exhibit 5.1 to the Registration Statement. In giving our consent, we do not admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations thereunder.

---

| |
|:---|
|  Very truly yours, |
|  /S/ GOODWIN PROCTER LLP |
|  GOODWIN PROCTER LLP |

---

![LOGO](g446122g0222091318103.jpg)

## Exhibit 23.1

**Exhibit 23.1** 

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM** 

We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the Kymera Therapeutics, Inc. 2020 Stock Option and Incentive Plan and Kymera Therapeutics, Inc. Amended and Restated 2020 Employee Stock Purchase Plan of our reports dated February 23, 2023, with respect to the consolidated financial statements of Kymera Therapeutics, Inc. and the effectiveness of internal control over financial reporting of Kymera Therapeutics, Inc. included in its Annual Report (Form 10-K) for the year ended December 31, 2022, filed with the Securities and Exchange Commission.

---

| |
|:---|
|  /s/ Ernst & Young LLP |
|  Boston, Massachusetts |
|  February 23, 2023 |

---

## Ex-Filing

**Exhibit 107** 

**Calculation of Filing Fee Table** 

<u>Form S-8</u> 

(Form Type)

<u>Kymera Therapeutics, Inc.</u> 

(Exact Name of Registrant as Specified in its Charter)

Table 1: Newly Registered Securities

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;Security<br>Type | Security<br> Class<br> Title | Fee<br>Calculation<br>Rule | Amount<br>Registered(1) | Proposed<br>Maximum<br>Offering<br>Price Per<br>Unit | Maximum<br> Aggregate<br> Offering<br>Price | Fee<br> Rate | Amount of<br>Registration<br>Fee |
| &nbsp;&nbsp;&nbsp;Equity | Kymera Therapeutics, Inc. 2020 Stock Option and Incentive Plan<br> Common Stock, $0.0001 par value per share | 457(c)<br>and<br> 457(h) | 2201575(2) | $32.35(3) | $71220951.25 | $0.00011020 | $7848.55 |
| &nbsp;&nbsp;&nbsp;Equity | Kymera Therapeutics, Inc. Amended and Restated 2020 Employee Stock Purchase Plan<br> Common Stock, $0.0001 par value per share | 457(c)<br>and<br> 457(h) | 438898(4) | $27.50(5) | $12069695.00 | $0.00011020 | $1330.08 |
| &nbsp;&nbsp;&nbsp;Total Offering Amounts | &nbsp;&nbsp;&nbsp;Total Offering Amounts | &nbsp;&nbsp;&nbsp;Total Offering Amounts | &nbsp;&nbsp;&nbsp;Total Offering Amounts |  | $83290646.25 |  | $9178.63 |
| &nbsp;&nbsp;&nbsp;Total Fee Offsets | &nbsp;&nbsp;&nbsp;Total Fee Offsets | &nbsp;&nbsp;&nbsp;Total Fee Offsets | &nbsp;&nbsp;&nbsp;Total Fee Offsets |  |  |  | $0 |
| &nbsp;&nbsp;&nbsp;Net Fee Due | &nbsp;&nbsp;&nbsp;Net Fee Due | &nbsp;&nbsp;&nbsp;Net Fee Due | &nbsp;&nbsp;&nbsp;Net Fee Due |  |  |  | $9178.63 |

---

(1) Pursuant to Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), this
registration statement shall also cover any additional shares of common stock which become issuable under the Kymera Therapeutics, Inc. 2020 Stock Option and Incentive Plan (the "Plan") and the Kymera Therapeutics, Inc. Amended and
Restated 2020 Employee Stock Purchase Plan (the "ESPP"), by reason of any stock dividend, stock split, recapitalization or any other similar transaction effected without the receipt of consideration which results in an increase in the
number of the Registrant's outstanding shares of common stock.

(2) Represents an automatic increase of 2,201,575 shares of Common Stock to the number of shares available for
issuance under the Plan, effective January 1, 2023. Shares available for issuance under the Plan were previously registered on registration statements on Form S-8 filed with the Securities and Exchange
Commission on August 21, 2020 (File No. 333-248249), March 11, 2021 (File No. 333-254122) and February 24, 2022 (File No. 333-262947).

(3) Estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and (h) of
the Securities Act, and based on the average of the high and low sale prices of the Registrant's common stock, as quoted on the Nasdaq Global Market, on February 21, 2023.

(4) Represents an automatic increase of 438,898 shares of Common Stock to the number of shares available for
issuance under the ESPP, effective January 1, 2023. Shares available for issuance under the ESPP were previously registered on registration statements on Form S-8 filed with the Securities and Exchange
Commission on August 21, 2020 (File No. 333-248249), March 11, 2021 (File No. 333-254122) and February 24, 2022 (File No. 333-262947).

(5) The price of $27.50 per share, which is 85% of the average of the high and low sale prices of the Common Stock
of the Registrant as quoted on the Nasdaq Global Market on February 21, 2023, is set forth solely for purposes of calculating the registration fee pursuant to Rules 457(c) and (h) of the Securities Act and has been used as these shares are
without a fixed price. Pursuant to the ESPP, the purchase price of the shares of Common Stock reserved for issuance thereunder will be 85% of the fair market value of a share of Common Stock on the first trading day of the offering period or on the
exercise date, whichever is less.